[1]JournalofMedicinalChemistry,2008,vol.51,p.1976-1980
[2]JournalofMedicinalChemistry,2006,vol.49,p.2143-2146
[1]Patent:US2007/249610,2007,A1.Locationinpatent:Page/Pagecolumn5;8-9
[1]OrganicProcessResearchandDevelopment,2015,vol.19,p.900-907
[2]Patent:US2007/249610,2007,A1.Locationinpatent:Page/Pagecolumn5;9-11
[3]JournalofMedicinalChemistry,2008,vol.51,p.1976-1980
[1]JournalofMedicinalChemistry,2006,vol.49,p.2143-2146
[1]JournalofMedicinalChemistry,2006,vol.49,p.2143-2146
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.
Journal: Journal of clinical pharmacology 20120601
Title: Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120401
Title: Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120401
Title: Reversible and pH-dependent weak drug-excipient binding does not affect oral bioavailability of high dose drugs.
Journal: The Journal of pharmacy and pharmacology 20120401
Title: Identification of the oxidative and conjugative enzymes involved in the biotransformation of brivanib.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20120101
Title: Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.
Journal: Cancer chemotherapy and pharmacology 20111201
Title: Comprehensive analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology 20111030
Title: Malignant peripheral nerve sheath tumour presenting as a pneumothorax.
Journal: The British journal of radiology 20111001
Title: Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110815
Title: Overcoming antiangiogenic resistance.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110815
Title: Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.
Journal: British journal of cancer 20110628
Title: A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110601
Title: Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20110501
Title: Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110401
Title: Brivanib alaninate for cancer.
Journal: Expert opinion on investigational drugs 20110401
Title: Future treatment option for hepatocellular carcinoma: a focus on brivanib.
Journal: Digestive diseases (Basel, Switzerland) 20110101
Title: Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Journal: Chemistry & biology 20101124
Title: Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20101101
Title: Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.
Journal: Anticancer research 20101101
Title: Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.
Journal: Breast cancer research and treatment 20101001
Title: Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors.
Journal: European journal of cancer (Oxford, England : 1990) 20100601
Title: The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.
Journal: Molecular cancer therapeutics 20100201
Title: Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Journal: Cancer chemotherapy and pharmacology 20091201
Title: Direct and indirect separations of five isomers of Brivanib Alaninate using chiral high-performance liquid chromatography.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081101
Title: Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20081001
Title: Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.
Journal: Bioorganic & medicinal chemistry letters 20080501
Title: Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).
Journal: Journal of medicinal chemistry 20080327
Title: By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy.
Journal: Breast cancer research : BCR 20080101
Title: Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist.
Journal: Cancer research 20070715
Title: Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.
Journal: Journal of medicinal chemistry 20060406
Title: Bhide RS, et al. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo,1-f,2,4triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem, 2006, 49 (7), 2143-2146.
Title: Huynh H, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res, 2008,
Title: Nakamura I, et al. Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. PLoS One. 2015 Nov 3;10(11):e0142355.
